Health Canada warns doctors not to start this prescription medication

- Health Canada has issued a warning to physicians advising them not to start new patients on the prescription medication TAVNEOS.
- The agency is currently reviewing the drug's evidence after concerns were raised regarding the integrity of data from its key clinical trial.
- This measure is critical to ensure patient safety and the efficacy of the treatment while the regulatory review is conducted.
- Doctors are instructed to maintain this restriction until Health Canada completes its investigation and provides further guidance on the drug's status.
Sources & Citations
1 sourceMore Stories
Health Brief: Hospitals face more policy headwinds - The Washington Post
• A federal judge has issued a temporary block on Colorado's first-in-the-nation prescription drug payment cap. • The ruling provides an early legal victory for the pharmaceutical company Amgen, which challenged the policy.
Read original · washingtonpost.comClinical Trial Launches to Test Bundibugyo Virus Treatments
• An international clinical trial has launched to evaluate potential treatments for Bundibugyo virus disease (BVD) as patient enrollment begins. • Sponsored by the WHO and coordinated by partners in the DRC, Belgium, and the UK, the study responds to an outbreak in the DRC where over 1,400 people have been diagnosed.
Read original · emjreviews.com
EMJWHO declares Hantavirus outbreak over - Tribune Online
• The World Health Organization (WHO) has officially declared the end of the hantavirus outbreak that was linked to the cruise ship MV Hondius. • While the hantavirus threat has subsided, the WHO issued a critical warning regarding an escalating Ebola outbreak in the Democratic Republic of the Congo (DRC).
Read original · tribuneonlineng.com
Tribune OnlineEbola: New trial to test treatments for unchallenged viral strain
• The World Health Organization (WHO) has launched participant enrollment for the PARTNERS clinical trial to investigate targeted treatments for the Bundibugyo virus. • This specific strain of the Ebola virus is responsible for the current outbreak, yet there are currently no approved preventive vaccines or targeted treatments available.
Read original · medicalnewstoday.com
Medical News TodayMonday, July 6, 2026 - KFF Health News
• The WHO announced the first patient has entered a randomized platform trial in the Democratic Republic of the Congo to test the monoclonal antibody MBP134 and remdesivir against the Bundibugyo virus. • This clinical trial aims to determine if these antiviral therapies, used alone or in combination, can improve survival rates as Ebola-related cases and deaths continue to rise.
Read original · kffhealthnews.orgResearch updates, July 7 - The Sick Times
• An autopsy study conducted as part of the NIH’s RECOVER program found that the SARS-CoV-2 virus can persist in the hearts of some individuals after they have died from COVID-19. • The researchers presented these unpublished findings via a poster at a pathology conference this spring to highlight the long-term presence of the virus in cardiac tissue.
Read original · thesicktimes.org
The Sick TimesThe Washington Post Investigated Why Measles Is Harder to Stop in 2026 Than It Was 10 Years Ago
• A Washington Post investigation reveals that 2026 measles outbreaks are more difficult to contain due to larger unvaccinated networks and a diminished public health response capacity. • State and local health departments lost approximately 10–20% of their epidemiological workforce between 2023 and 2025 as pandemic-era emergency funding and hiring were reversed.
Read original · medicaldaily.com
Medical DailyThere's no treatment designed for the Ebola strain ravaging DRC. But now there's hope : NPR
• The Democratic Republic of the Congo (DRC) is currently battling an Ebola outbreak caused by a viral strain for which no specific treatments or preventive measures currently exist. • To address this medical gap, three new clinical trials have been launched to test potential breakthroughs in treating and preventing the virus.
Read original · npr.orgFDA’s regulatory outlook - POLITICO
• The Trump administration has released its 2026 regulatory agenda, which includes several key initiatives focused on the pharmaceutical industry. • Acting FDA Commissioner Kyle Diamantas emphasized a renewed focus on the agency's core mission, specifically regarding medications, diagnostics, treatments, and medical devices.
Read original · politico.comFDA Action Update, June 2026: Acceptances, Clearances, and Alignments
• The FDA issued several decisions in June 2026 regarding new neurology therapeutic agents, including new drug application acceptances and regulatory alignments. • Key Duchenne Muscular Dystrophy (DMD) actions include the acceptance of Sarepta’s sNDAs to transition casimersen and golodirsen to traditional approvals.
Read original · neurologylive.comWHO clears first emergency diagnostic test for Bundibugyo Ebola - The Standard Health
• The World Health Organization (WHO) has added the first molecular diagnostic test for the Bundibugyo strain of Ebola virus to its Emergency Use Listing (EUL). • This risk-based procedure allows countries and procurement agencies to rapidly access quality-assured diagnostics before full regulatory approvals are finalized.
Read original · standardmedia.co.ke

